Sunday, October 21, 2018 4:45:45 PM
Rett trial moving to Austrailia.
Very Interesting, Looks like TGD has all the bases covered.
part 1 in USA?
Part 2 Down under? (rett and aussie grants)
From Facebook
Rett Syndrome Association of Australia - RSAA shared a post.
October 19 at 7:49 AM ·
Today i met with the CEO of Anavex Life Sciences Corp. NY to discuss the possibility of a clinical trial of their novice drug ANAVEX2-73 to treat Rett Syndrome patients, right here in Australia. The drug has shown very promising results in pre-clinical trials and an application was made to move to a clinical trial, While I was with Christopher he took a phone call advising him that their FDA approval to commence that trial was granted in the USA which is a major milestone in any commercial trial. These discussions are still in early stages however Anavex has agreed to run a trial here with our girls, The RSAA will post updates and information on both Facebook and the RSAA website (i will do my best to upload a presentation on the drug this weekend) but in the mean time please see attached FDA announcement.
Facebook
Very Interesting, Looks like TGD has all the bases covered.
part 1 in USA?
Part 2 Down under? (rett and aussie grants)
From Facebook
Rett Syndrome Association of Australia - RSAA shared a post.
October 19 at 7:49 AM ·
Today i met with the CEO of Anavex Life Sciences Corp. NY to discuss the possibility of a clinical trial of their novice drug ANAVEX2-73 to treat Rett Syndrome patients, right here in Australia. The drug has shown very promising results in pre-clinical trials and an application was made to move to a clinical trial, While I was with Christopher he took a phone call advising him that their FDA approval to commence that trial was granted in the USA which is a major milestone in any commercial trial. These discussions are still in early stages however Anavex has agreed to run a trial here with our girls, The RSAA will post updates and information on both Facebook and the RSAA website (i will do my best to upload a presentation on the drug this weekend) but in the mean time please see attached FDA announcement.
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
